Literature DB >> 11927282

STI571 (Gleevec) as a paradigm for cancer therapy.

Brian J Druker1.   

Abstract

STI571 (Gleevec, imatinib mesylate) exemplifies the successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer. This article reviews the identification of Bcr-Abl as a therapeutic target in chronic myelogenous leukemia and the steps in the development of an agent to inactivate this abnormality. Issues related to clinical trials of molecularly targeted agents are discussed, including dose and patient selection and possible mechanisms of resistance to STI571. Finally, the potential use of STI571 with different tumors and the translation of this paradigm to other malignancies are explored.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11927282     DOI： 10.1016/s1471-4914(02)02305-5

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  56 in total

1.  Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis.

Authors:  Xunqin Yin; Mary Ellen Pavone; Zhenxiao Lu; JianJun Wei; J Julie Kim
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

Review 2.  Targeting the Jak/STAT pathway for immunosuppression.

Authors:  J J O'shea
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

3.  Apoptosis in cancer: archaeology, functional relevance and exploitation in novel treatment strategies.

Authors:  E F Gaffney
Journal:  Ir J Med Sci       Date:  2004 Jan-Mar       Impact factor: 1.568

Review 4.  DNA repair and personalized breast cancer therapy.

Authors:  Shu-Xia Li; Ashley Sjolund; Lyndsay Harris; Joann B Sweasy
Journal:  Environ Mol Mutagen       Date:  2010 Oct-Dec       Impact factor: 3.216

Review 5.  BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Authors:  Wanlong Ma; Hagop Kantarjian; Chen-Hsiung Yeh; Zhong J Zhang; Jorge Cortes; Maher Albitar
Journal:  Acta Haematol       Date:  2009-03-31       Impact factor: 2.195

6.  New approaches to targeted therapy in lung cancer.

Authors:  William Pao
Journal:  Proc Am Thorac Soc       Date:  2012-05

7.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue.

Authors:  Brian J Albert; Ananthapadmanabhan Sivaramakrishnan; Tadaatsu Naka; Nancy L Czaicki; Kazunori Koide
Journal:  J Am Chem Soc       Date:  2007-02-06       Impact factor: 15.419

8.  Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

Authors:  Sean L Petersen; Lai Wang; Asligul Yalcin-Chin; Lin Li; Michael Peyton; John Minna; Patrick Harran; Xiaodong Wang
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

Review 9.  Neointimal hyperplasia associated with synthetic hemodialysis grafts.

Authors:  Li Li; Christi M Terry; Yan-Ting E Shiu; Alfred K Cheung
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

10.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.